Cardiologs co-founder and CEO Yann Fleureau was named the European Innovator of the Year by MIT Technology Review. The company offers a cloud-based artificial intelligence (AI) platform that enables the detection of 14 cardiac arrhythmias through ambulatory electrocardiogram (ECG) readings.

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

Women with a history of cardiotoxicity from previous cancer treatments are around 30 percent more likely to experience clinical congestive heart failure (CHF) before, during or after pregnancy, according to research published ahead of print in the Journal of the American College of Cardiology.

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.

A simplified cardiac magnetic resonance (CMR) protocol using a contrast agent allowed clinicians in Peru to diagnose heart ailments more quickly and cheaply, a new study found. The results, published online Aug. 29 in the Journal of the American Heart Association, highlight a potential pathway to realizing the benefits of CMR in developing nations.

Vienna, VA (August 13, 2018) — B. Kelly Han, MD, is the recipient of the inaugural 2018 DeHaan Award for Innovation in Cardiology, which includes a $200,000 grant.

The U.S. Preventive Task Force (USPSTF) issued a Grade I recommendation, indicating there is insufficient evidence assessing the benefits and harms of screening for atrial fibrillation (AFib) with electrocardiography (ECG) in patients 65 and older with previously undiagnosed AFib.

While heart failure (HF) is an uncommon complication of breast cancer, a new study in the Journal of the American College of Cardiology notes individuals treated with trastuzumab-based chemotherapy have a higher risk for HF—but they are not monitored for it, despite recommendations.